 |
|
|
| |
Outcomes After Switching From 144 Weeks of
Blinded DTG/ABC/3TC to 96 Weeks of Open-label B/F/TAF
|
| |
| |
Glagow 2022 Oct 23-26
Chloe Orkin, Andrea Antinori, Jürgen Rockstroh, Santiago Moreno Guillén, Claudia Martorell, Jean-Michel Molina, Adriano Lazzarin, Franco Maggiolo, Yazdan Yazdanpanah, Kristen Andreatta, Hailin Huang, Jason Hindman, Hal Martin, Jared Baeten, Anton Pozniak11
1Queen Mary University of London, UK; 2Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Roma, Italy; 3Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn, Germany; 4Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain; 5Infectious Diseases and the Research Institute,
Springfield, Massachusetts, US; 6University of Paris, France; 7IRCCS Ospedale San Raffaele, Milano, Italy; 8Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; 9Hôpital Bichat-Claude Bernard, Paris; 10Gilead Sciences, Inc., Foster City, California, US; 11Chelsea and Westminster Hospital, London
|
| |
|
|
|
|
|
